Clinical trials: Neoadjuvant Treatment
Crohn's Disease
Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)
This 26-week extension study evaluates the efficacy and safety of certolizumab pegol administered subcutaneously every 4 weeks (dosed at Weeks 16, 20, 24, 28 and 32) in subjects with active Crohn's disease who had no clinical…
- Trial name
- NCT00329420
- Testing
- Certolizumab pegol
- Where
- 23 sites in Japan
- Volunteers
- 46 people
- Sponsor
- UCB Pharma
Breast Cancer
Positive Node Traced Before Neoadjuvant Chemotherapy (NAC)
To investigate this regression model by injecting and tracing carbon nanoparticles (CNs) into the fusion node prior to NAC in patients with breast cancer.
- Trial name
- NCT03355261
- Testing
- complete remission (CR) group, partial remission (PR) group, stable disease (SD) group
- Where
- 3 sites in China
- Volunteers
- 110 people
- Sponsor
- Shengjing Hospital
Renal Failure, Chronic, Renal Transplantation
Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients
The aim of this randomized prospective study in renal transplant recipients is to investigate immunological short and long-term effects of an IVIG induction therapy.
- Trial name
- NCT00176059
- Testing
- intravenous immunoglobulins (IVIG), kidney transplantation
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Giessen
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer
2-Drug Combination Chemotherapy Followed by Radiotherapy. Paclitaxel, TAX, NSC-125973; Cisplatin, CDDP, NSC-119875; followed by chest irradiation using 4-15 MV photons.
- Trial name
- NCT00001499
- Testing
- paclitaxel, cisplatin, chest radiotherapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Non Squamous Non Small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation
This study was designed to investigate the efficacy and safety of neoadjuvant Toripalimab (anti-PD1) plus chemotherapy for patients with resectable II-IIIB non-squamous NSCLC harboring EGFR mutation, and to explore the potential…
- Trial name
- NCT05962021
- Testing
- Toripalimab plus Chemotherapy
- Volunteers
- 126 people
- Sponsor
- Peking University People's Hospital
Prehabilitation, Breast Cancer
Prehabilitation With Resistance-exercise Training for Breast Cancer Neoadjuvant Therapy
Breast cancer stands as the foremost cause of cancer-related deaths among women worldwide, with the highest incidence of any cancer type.
- Conditions
- Prehabilitation, Breast Cancer, Postmenopause, Resistance Training
- Trial name
- NEO STRONG (NCT06309290)
- Testing
- Prehabilitation with resistance-exercise training, Usual care program
- Where
- 2 sites in Chile
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Universidad de La Frontera
Gastric Cancer
Real World Evidence for the Cycle of Neoadjuvant Chemotherapy in Gastric Cancer With Shared Decision Making
The purpose of the study is to evaluate the maximal cycle of effective neoadjuvant chemotherapy for resectable gastric cancer, to determine what is the best cycle of neoadjuvant chemotherapy for the patients who receive…
- Trial name
- RECOMMEND (NCT03413514)
- Testing
- NACT, SDM, Surgery
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University
Breast Cancer
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, paclitaxel, and gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070278
- Testing
- cyclophosphamide, epirubicin hydrochloride, gemcitabine hydrochloride
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Invasive Breast Cancer
Computed Tomography (CT) Reconstruction for Axillary Lymph Node Structure
This is a prospective, single-center, non-randomized, non-controlled observational study.
- Trial name
- CTREP (NCT03247478)
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking University
Triple Negative Breast Cancer
De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
The traditional neoadjuvant therapy for triple negative breast cancer is based on anthracycline, paclitaxel and carboplatin. Nowadays, immunotherapy combined with chemotherapy has become a new standard treatment, which not only…
- Trial name
- NacTNBC (NCT06692725)
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Peking University People's Hospital
Brainstem Glioma, Neoadjuvant Therapy
Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas
Oncolytic adenovirus for pediatric naive DIPG, to be infused after tumor biopsy through the same trajectory in the cerebellar peduncle.
- Trial name
- NCT03178032
- Testing
- DNX-2401
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Breast Neoplasms
Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
- Trial name
- NCT00174343
- Testing
- exemestane (Aromasin®)
- Where
- 5 sites in France
- Volunteers
- 46 people
- Sponsor
- Pfizer
Breast Cancer
Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients
This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)
- Trial name
- NCT02995772
- Testing
- Aromatase Inhibitors (Arimidex), Tamoxifen, SOB
- Where
- Indonesia
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Dharmais National Cancer Center Hospital
Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection
Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
The goal of this observational study is to learn whether tumor and nodal downstaging after neoadjuvant chemo-immunotherapy is associated with better surgical outcomes in patients with clinical stage IIB-III non-small cell lung…
- Conditions
- Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, Stage IIB-III NSCLC
- Trial name
- DRAGON-NSCLC (NCT07528066)
- Testing
- Robotic-assisted surgery (RATS)
- Where
- 10 sites in China, France and 1 more
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
Colorectal Liver Metastases
Impact of Preoperative Chemotherapy on Complications and Regeneration After Resection of Colorectal Liver Metastases
The objective of this study is to evaluate for the first time not only the impact of neoadjuvant chemotherapy on clinical outcome, but also on liver regeneration after liver resection.
- Trial name
- NCT00779272
- Where
- Switzerland
- Volunteers
- 184 people
- Sponsor
- University of Zurich
Rectal Neoplasms
Prediction of Response to Neoadjuvant Therapy in Rectal Cancer
The purpose of this study is to determine whether 18F-FDG-PET-CT and texture analysis of MRI performed 9 weeks after Neoadjuvant Chemo-radiotherapy in patients with locally advanced rectal cancer has the ability to identify…
- Trial name
- PRENT-LARC (NCT02439086)
- Testing
- PET-CT Scan
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Colchester General Hospital
Breast Cancer
Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer
Phase II trial of Neoadjuvant [FEC100]/Cisplatin-Docetaxel ± Trastuzumab in women with over expressed or amplified Her2/Neu with Locally advanced Breast Cancer
- Trial name
- NCT00535509
- Testing
- Cisplatin-Docetaxel ± Trastuzumab
- Volunteers
- 285 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Nasopharyngeal Carcinoma
Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRT
The gross tumor volumes of the primary site and the neck nodes (GTVnx and GTVnd) could be delineated according to the post-NACT tumor position and receive radical radiation dose, while the tumor disappear after NACT could be…
- Trial name
- NCT03283293
- Testing
- Target Volume Delineation after NACT
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-sen University
Ulcerative Colitis
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of patient-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis…
- Trial name
- FIGARO UC 302 (NCT03259308)
- Testing
- Ontamalimab
- Where
- 207 sites in United States, Argentina and 20 more
- Volunteers
- 279 people
- Sponsor
- Shire
Gastric Cancer
Hematological Dynamic Scores for Predicting Survival and Treatment Response for Advanced Gastric Cancer After Neoadjuvant Therapy
HMDLS, based on hematological markers, could effectively distinguish the long-term efficacy of AGC patients after NAT. The predictive performance of nomogram-HMDLS was better than ypTNM stage, achieving better prognostic…
- Trial name
- NCT06573307
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Chang-Ming Huang, Prof.